Arena Updates Etrasimod Timelines, Introduces New Drug Candidate
Late-Stage S1P Modulator Data Due Later In 2021, Early In 2022
Executive Summary
CEO Amit Munshi told the J.P. Morgan meeting the company will double the size of its clinical-stage cardiovascular disease pipeline with the addition of temanogrel.
You may also be interested in...
Zeposia’s Ulcerative Colitis Approval Provides BMS’s Beachhead Into GI
The second US approval for the S1P receptor agonist brings Bristol into the gastrointestinal space, and is just the starting point for the pharma in that arena, the company told Scrip.
Arena Sees Phase III Path For Etrasimod After Atopic Dermatitis Miss
Arena said its S1P receptor modulator missed the primary endpoint in a Phase IIb trial but data from patients with uninterrupted treatment justify moving etrasimod into a pivotal program.
BMS Sees Zeposia As Safer Oral Option In Ulcerative Colitis
Bristol Myers Squibb reported detailed results from the Phase III TRUE NORTH study that show durable remissions in a patient population that switches therapies due to loss of response.